Celltrion
068270.KS
$125.33
Share price
-2.37%
Change (1 day)
-3.54%
Change (1 year)
Categories
Celltrion is a Korean pharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion.
Revenue for Celltrion (068270.KS)
Revenue in 2023 (TTM): $1.64 B
According to Celltrion 's latest financial reports the company's current revenue (TTM) is $1.64 B. In 2022 the company made a revenue of $1.75 B an increase over the years 2021 revenue that were of $1.64 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Celltrion from 2008 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $1.64 B | -5.9% |
| 2022 | $1.75 B | 6.49% |
| 2021 | $1.64 B | 3.45% |
| 2020 | $1.59 B | 64.11% |
| 2019 | $0.96 B | 8.61% |
| 2018 | $0.89 B | 4.96% |
| 2017 | $0.85 B | 46.26% |
| 2016 | $0.58 B | 11.08% |
| 2015 | $0.52 B | 16.53% |
| 2014 | $0.44 B | 117.1% |
| 2013 | $0.20 B | -35.55% |
| 2012 | $0.32 B | |
| 2010 | $0.15 B | 34.6% |
| 2009 | $0.11 B | 61.86% |
| 2008 | $71.98 M |